Thryv licenses SGK1 inhibitors from CSIC/UAM
Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 03, 2026
The licensing agreement expands Thryv's pipeline into neurodegenerative diseases, potentially increasing its valuation and attractiveness to investors. It also strengthens Thryv's intellectual property portfolio with a second independent SGK1 inhibitor scaffold, which may enhance its competitive position in the biopharmaceutical market.
Ajax Therapeutics Inc., a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors, announced on September 3, 2026 that it entered into an exclusive, worldwide, royalty-bearing patent and know-how license agreement with the Spain — Spanish National Research Council (CSIC), the Autonomous University of Madrid (UAM), and Fundación de la Universidad Autónoma de Madrid (FUAM). The agreement, effective July 1, 2026, grants Thryv rights across all fields of use and territories, with the right to sublicense. The licensed invention is a structurally distinct SGK1 inhibitor scaffold developed by research groups led by Ana Martínez, Carmen Gil, Eduardo Oliver Pérez at CSIC, and Isabel Lastres-Becker and Ana Briones Alonso at UAM. This second independent chemical series is intended to enable Thryv to develop compounds designed to reach the brain, targeting neurodegenerative diseases such as Parkinson's and Alzheimer's, while its existing cardiac programs continue. Thryv's lead asset, THRV-1268, is in clinical studies for Long QT Syndrome Type 2 and heart failure. The newly licensed series will undergo initial characterization immediately, with a first development candidate targeted for 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard